Pivotal bioVenture Partners CNS Fund I SLP, L.P. — Form D
Pivotal bioVenture Partners CNS Fund I SLP, L.P. of SAN FRANCISCO, CA, a pooled investment fund, filed a Form D exempt-offering notice with the SEC on 2021-08-27. $1.1M was reported sold. Industry: Pooled Investment Fund.
Offering
- Filed: 2021-08-27
- Form: D
- Accession: 0001880426-21-000001
- Industry: Pooled Investment Fund
- Exemptions: 06b, 3C, 3C.1, 3C.7
- Amount sold: $1.1M
- Investors: 6
- Date of first sale: 2021-08-10
- Security types: equity, fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-411487
Issuer
- Name: Pivotal bioVenture Partners CNS Fund I SLP, L.P.
- CIK: 0001880426
- Entity type: Limited Partnership
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 501, SECOND STREET, SUITE 200, SAN FRANCISCO, CA, 94017
- Phone: 408-838-2273
Officers, directors & promoters (3)
| Name | Role | Location |
|---|
| Peter Tuxen Bisgaard | Director | San Francisco, CA |
| Vincent Sai Sing Tuxen Cheung | Director | Hong Kong, China, K3 |
| Richard Tuxen Coles | Director | Grand Cayman, E9 |
More